Midkine and pleiotrophin: Two related proteins involved in development, survival, inflammation and tumorigenesis

被引:315
作者
Muramatsu, T [1 ]
机构
[1] Nagoya Univ, Sch Med, Dept Biochem, Showa Ku, Aichi 4668550, Japan
关键词
cancer therapy; cell migration; cell survival; protein tyrosine phosphatase; tumor marker;
D O I
10.1093/oxfordjournals.jbchem.a003231
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Midkine (MK) and pleiotrophin (PTN) are low molecular weight proteins with closely related structures. They are mainly composed of two domains held by disulfide bridges, and there are three antiparallel beta-sheets in each domain. MK and PTN promote the growth, survival, and migration of various cells, and play roles in neurogenesis and epithelial mesenchymal interactions during organogenesis. A chondroitin sulfate proteoglycan, protein-tyrosine phosphatase zeta (PTPzeta), is a receptor for MK and PTN. The downstream signaling system includes ERK and PI3 kinase. MK binds to the chondroitin sulfate portion of PTPzeta with high affinity. Among the various chondroitin sulfate structures, the E unit, which has 4,6-disulfated N-acetylgalactosamine, provides the strongest binding site. The expression of MK and PTN is increased in various human tumors, making them promising as tumor markers and as targets for tumor therapy. MK and PTN expression also increases upon ischemic injury. MK enhances the migration of inflammatory cells, and is involved in neointima formation and renal injury following ischemia. MK is also interesting from the viewpoints of the treatment of neurodegenerative diseases, increasing the efficiency of in vitro development, and the prevention of HIV infection.
引用
收藏
页码:359 / 371
页数:13
相关论文
共 184 条
[1]  
Adachi Y, 2001, CANCER RES, V61, P7882
[2]  
Adachi Y, 1996, ONCOGENE, V13, P2197
[3]  
Adachi Y, 2000, CANCER RES, V60, P4305
[4]  
Akhter S, 1998, J BIOCHEM-TOKYO, V123, P1127
[5]   Enhanced hippocampal long-term potentiation in mice lacking heparin-binding growth-associated molecule [J].
Amet, LEA ;
Lauri, SE ;
Hienola, A ;
Croll, SD ;
Lu, Y ;
Levorse, JM ;
Prabhakaran, B ;
Taira, T ;
Rauvala, H ;
Vogt, TF .
MOLECULAR AND CELLULAR NEUROSCIENCE, 2001, 17 (06) :1014-1024
[6]   INCREASED MIDKINE GENE-EXPRESSION IN HUMAN GASTROINTESTINAL CANCERS [J].
ARIDOME, K ;
TSUTSUI, J ;
TAKAO, S ;
KADOMATSU, K ;
OZAWA, M ;
AIKOU, T ;
MURAMATSU, T .
JAPANESE JOURNAL OF CANCER RESEARCH, 1995, 86 (07) :655-661
[7]   Truncated midkine as a marker of diagnosis and detection of nodal metastases in gastrointestinal carcinomas [J].
Aridome, K ;
Takao, S ;
Kaname, T ;
Kadomatsu, K ;
Natsugoe, S ;
Kijima, F ;
Aikou, T ;
Muramatsu, T .
BRITISH JOURNAL OF CANCER, 1998, 78 (04) :472-477
[8]   Identification of heparin-binding sites in midkine and their role in neurite-promotion [J].
Asai, T ;
Watanabe, K ;
IchiharaTanaka, K ;
Kaneda, N ;
Kojima, S ;
Iguchi, A ;
Inagaki, F ;
Muramatsu, T .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1997, 236 (01) :66-70
[9]   The lysine-rich C-terminal tail of heparin affin regulatory peptide is required for mitogenic and tumor formation activities [J].
Bernard-Pierrot, I ;
Delbé, J ;
Caruelle, D ;
Barritault, D ;
Courty, J ;
Milhiet, PE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (15) :12228-12234
[10]   Inhibition of HIV infection by the cytokine midkine [J].
Callebaut, C ;
Nisole, S ;
Briand, JP ;
Krust, B ;
Hovanessian, AG .
VIROLOGY, 2001, 281 (02) :248-264